SOURCE: Market Pulse

December 08, 2005 08:30 ET

Market Pulse Breaking News Alert for Thursday, Dec. 8, 2005: DNAG -- DNAPrint genomics to Participate in Pharmacogenomics E-Symposium!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Market Pulse.

ATLANTA, GA -- (MARKET WIRE) -- December 8, 2005 -- Market Pulse News Alert for this AM, Stocks to Watch are: DNAPrint genomics, Inc. (OTC BB: DNAG), Spherix Inc. (NASDAQ: SPEX), Microsoft Corp. (NASDAQ: MSFT) and Cisco Systems Inc. (NASDAQ: CSCO).

Investors need to be watching DNAPrint genomics, Inc. (OTC BB: DNAG) this AM! DNAPrint is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology, and consumer genetic tests. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWitness(tm), RETINOME(tm) (a predictive test for inferring eye color from a DNA sample), ANCESTRYbyDNA(tm), and EURO-DNA(tm). DNAPrint's management sees exciting growth opportunity in these markets to introduce and sell their novel products and services. DNAG just had excellent news out in a press release before Thursday's opening bell announcing that the company will participate in a live electronic symposium hosted by the International Society of Pharmacogenomics on Monday, December 12th. This could be great news for investors!

DNAPrint genomics, Inc. (OTC BB: DNAG) announced today that the company will participate in a live electronic symposium hosted by the International Society of Pharmacogenomics on Monday, December 12.

DNAPrint genomics Founder and Chief Scientific Officer Tony N. Frudakis will make a presentation about the role the company's wholly owned DNAPrint Pharmaceuticals, Inc., subsidiary is playing in the development of personalized medicines utilizing human population genetics technology. He will focus on genomic-based pharmacogenomic test/drug combinations called "theranostics," which are designed to improve efficacy and reduce side effects by matching a patient with the most appropriate drug. Dr. Frudakis' portion of the webcast event, scheduled for 11:30 a.m. Eastern time, can be accessed at http://www.pharmcogen.e-symposium.com.

DNA Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D., will participate in a panel discussion and roundtable focusing on the role pharmacogenomics has to play in treating cardiac patients. The Cardiovascular Pharmacogenomics roundtable is scheduled to start at 1:30 p.m. Eastern time and also can be accessed at http://www.pharmcogen.e-symposium.com.

"The Pharmacogenomics E-Symposium™ brings together officials, regulators and researchers from within the global pharmaceutical industry," stated DNAPrint President and Chief Executive Officer Richard. Gabriel. "It is an excellent platform for providing broad industry exposure for DNAPrint Pharmaceuticals, Inc., our newly formed pharmaceutical subsidiary."

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. (www.dnaprint.com), through its DNAPrint Pharmaceutics, Inc., wholly owned subsidiary, is a developer of genomics-based products and services focused on drug development, computational biology and pharmacogenomic diagnostic tests. Computational biology and pharmacogenomics services are also offered externally to biopharmaceutical companies. The company's first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint also develops and markets products for the law enforcement forensics and consumer markets that include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™.

Stocks in the news and acting well as of late include: Spherix Inc. (NASDAQ: SPEX), Microsoft Corp. (NASDAQ: MSFT) and Cisco Systems Inc. (NASDAQ: CSCO).

Information contained herein is the opinion of Market-Pulse.com ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated one hundred fifty thousand dollars from DNAPrint genomics, Inc. MP was also compensated two million restricted shares of common stock directly from DNAPrint genomics, Inc. In addition, MP has two million restricted shares of common stock pending directly from DNAPrint genomics, Inc. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives free trading shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. Market-Pulse.com and Market Pulse Breaking News Alert are owned by Market Pulse LLC.

Contact Information